The U.S. Food and Drug Administration (FDA) has approved Hympavzi (marstacimab-hncq) for routine prophylaxis aimed at ...

XOMA Royalty Corporation offers high-yield dividends and stable returns through preferred shares, making them a strong buy ...

LEXINGTON, Mass. and AMSTERDAM, Oct. 15, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing ...

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating ... reflecting the company’s diverse pipeline and the promising prospects in Hemophilia A and transthyretin amyloidosis programs.

The FDA has approved a new preventive treatment for people with certain types of hemophilia that can reduce bleeding episodes, sometimes down to just a few per year.

Applying electrical stimulation to a major nerve that runs from the brain to the body might help to promote clotting.

Lundbeck A/S is to acquire Longboard Pharmaceuticals Inc. in an all-cash deal valuing the epilepsy specialist at $2.6 billion. The agreed price of $60 per share is a 54% premium to the closing price ...

Pfizer Inc. has won regulatory approval for its hympavzi drug as a treatment for hemophilia A or B without inhibitors - making it the first antitissue-factor pathway inhibitor to be allowed for the ...

The Food and Drug Administration approved Pfizer's Hympavzi to prevent or reduce bleeding episodes in patients with certain kinds of hemophilia, the pharmaceutical company said. Write to Rob Curran at ...

Hympavzi, also known as marstacimab, can be given with weekly subcutaneous administration for routine prophylaxis in patients age 12 and up as an alternative to intravenous infusions that are often ...

Although the Atlantic hurricane season officially ends Nov. 30, scientists say there is still the possibility for more named ...

U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors ...